A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers
NCT ID: NCT00619931
Last Updated: 2022-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
50 participants
INTERVENTIONAL
2008-01-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers
NCT02140281
A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants
NCT04013191
A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects
NCT00854659
A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males
NCT02411500
Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012
NCT05017987
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
APD791 or placebo
APD791
APD791 or matching placebo in escalating doses
2
APD791 or placebo
APD791
APD791 or matching placebo in escalating doses
3
APD791 or placebo
APD791
APD791 or matching placebo in escalating doses
4
APD791 or placebo
APD791
APD791 or matching placebo in escalating doses
5
APD791 or placebo
APD791
APD791 or matching placebo in escalating doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
APD791
APD791 or matching placebo in escalating doses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non smokers
Exclusion Criteria
* Use of any drug known to have an effect on coagulation or clotting or any anti-platelet therapy within 2 weeks of the screening
* Recently donated blood or had significant blood loss
* Current use of a prescription medication
* Pregnant females
19 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arena Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Kisicki, MD
Role: PRINCIPAL_INVESTIGATOR
MDS Pharma Services
Christen M Anderson, MD, PhD
Role: STUDY_DIRECTOR
Arena Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MDS Pharma Services
Lincoln, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Arena Home Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APD791-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.